瑞士Novocure公司胰腺癌治疗迎新突破，旗下Optune Pax获欧盟CE认证

环球市场播报06-30

瑞士肿瘤疗法公司Novocure近日宣布，其创新医疗器械Optune Pax已获得欧盟CE认证，用于联合吉西他滨和白蛋白紫杉醇化疗方案，一线治疗局部晚期不可切除的胰腺癌成人患者。　　Optune Pax是一款便携式可穿戴设备，通过粘贴于腹部的电极贴片，向肿瘤部位传递低强度（150kHz）的交变电场，即肿瘤电场治疗。该疗法利用特定频率的电场物理性地干扰癌细胞有丝分裂过程中关键蛋白的排布，从而抑制其...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2647559731?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-30 21:14","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2647559731","market":"sg","top_or_hot":-1,"title":"瑞士Novocure公司胰腺癌治疗迎新突破，旗下Optune Pax获欧盟CE认证","media":"环球市场播报","content":"<div>\n<p>瑞士肿瘤疗法公司Novocure近日宣布，其创新医疗器械Optune Pax已获得欧盟CE认证，用于联合吉西他滨和白蛋白紫杉醇化疗方案，一线治疗局部晚期不可切除的胰腺癌成人患者。\n　　Optune Pax是一款便携式可穿戴设备，通过粘贴于腹部的电极贴片，向肿瘤部位传递低强度（150kHz）的交变电场，即肿瘤电场治疗。该疗法利用特定频率的电场物理性地干扰癌细胞有丝分裂过程中关键蛋白的排布，从而抑制其...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcpn1408992.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞士Novocure公司胰腺癌治疗迎新突破，旗下Optune Pax获欧盟CE认证</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞士Novocure公司胰腺癌治疗迎新突破，旗下Optune Pax获欧盟CE认证\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-30 21:14 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcpn1408992.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>瑞士肿瘤疗法公司Novocure近日宣布，其创新医疗器械Optune Pax已获得欧盟CE认证，用于联合吉西他滨和白蛋白紫杉醇化疗方案，一线治疗局部晚期不可切除的胰腺癌成人患者。\n　　Optune Pax是一款便携式可穿戴设备，通过粘贴于腹部的电极贴片，向肿瘤部位传递低强度（150kHz）的交变电场，即肿瘤电场治疗。该疗法利用特定频率的电场物理性地干扰癌细胞有丝分裂过程中关键蛋白的排布，从而抑制其...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcpn1408992.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-iniffcpn1408992.shtml","article_id":"2647559731","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647559731","pubTimestamp":1782825240,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"瑞士肿瘤疗法公司Novocure近日宣布，其创新医疗器械Optune Pax已获得欧盟CE认证，用于联合吉西他滨和白蛋白紫杉醇化疗方案，一线治疗局部晚期不可切除的胰腺癌成人患者。结果显示，在意向治疗人群中，接受Optune Pax联合化疗的患者中位总生存期达到16.2个月，而单独化疗组为14.2个月，延长了整整2个月，死亡风险降低了18%。Novocure公司表示，将尽快推动在德国等欧洲主要国家的上市工作，为这一长期缺乏有效新疗法的领域提供有意义的治疗突破。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4109":"特种化学制品","BK4588":"碎股","BK4585":"ETF&股票定投概念","CE":"塞拉尼斯"},"translate_title":"Swiss Novocure Company ushered in a new breakthrough in pancreatic cancer treatment, and its Optune Pax obtained EU CE certification","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CE":1.5,"FSXEmain":1.5,"FESXmain":1.5},"content_text":"瑞士肿瘤疗法公司Novocure近日宣布，其创新医疗器械Optune Pax已获得欧盟CE认证，用于联合吉西他滨和白蛋白紫杉醇化疗方案，一线治疗局部晚期不可切除的胰腺癌成人患者。\n　　Optune Pax是一款便携式可穿戴设备，通过粘贴于腹部的电极贴片，向肿瘤部位传递低强度（150kHz）的交变电场，即肿瘤电场治疗。该疗法利用特定频率的电场物理性地干扰癌细胞有丝分裂过程中关键蛋白的排布，从而抑制其增殖并诱导细胞死亡，由于正常细胞与癌细胞在电学特性上存在差异，该疗法对健康组织的损伤有限。\n　　此次获批主要基于一项名为PANOVA-3的关键性III期临床试验数据。该研究在全球196个中心招募了571名患者，是近年来胰腺癌领域规模最大的前瞻性随机对照试验之一。结果显示，在意向治疗人群中，接受Optune Pax联合化疗的患者中位总生存期达到16.2个月，而单独化疗组为14.2个月，延长了整整2个月，死亡风险降低了18%。在符合方案人群中使用设备超过28天中，中位生存期达到了18.3个月，较对照组的15.1个月延长了3.2个月。\n　　除了延长生存期，该疗法在缓解癌症相关疼痛方面也表现出显著优势。数据显示，联合治疗组的中位疼痛进展时间从对照组的9.1个月显著延长至15.2个月，提升了6.1个月。安全性方面，最常见的副作用为与电极片接触相关的皮肤反应，多为轻中度，并未增加化疗的系统性毒性。\n　　胰腺癌素有“癌中之王”之称，预后极差，五年生存率仅约13%。此次CE认证是该继获得美国FDA批准后的又一重大里程碑。Novocure公司表示，将尽快推动在德国等欧洲主要国家的上市工作，为这一长期缺乏有效新疗法的领域提供有意义的治疗突破。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647559731","isCrawlerRequest":true}